Publications by authors named "Edward B Reilly"

Claim this Profile
A
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing Tumors.
Jennifer D Stone, Kamonwan Fish, Devika Ashok, Laura M McKay, Saeed S Akhand, Edward B Reilly

Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.
Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Edward B Reilly

Leuk Lymphoma· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS.
Robert K Suter, Anna M Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Edward B Reilly

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.
Sonia Jain, Jessica I Griffith, Kendra A Porath, Sneha Rathi, Jiayan Le, Edward B Reilly

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Maissa Mhibik, Erika M Gaglione, David Eik, John Herrick, Janet Le, Edward B Reilly

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Adam S Chervin, Jennifer D Stone, Iwona Konieczna, Kelly M Calabrese, Ningyan Wang, Edward B Reilly

Mol Cancer Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar, Edward B Reilly

Neurooncol Adv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
Kendra A Porath, Michael S Regan, Jessica I Griffith, Sonia Jain, Sylwia A Stopka, Edward B Reilly

Neurooncol Adv· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodistribution Analysis of an Anti-EGFR Antibody in the Rat Brain: Validation of CSF Microcirculation as a Viable Pathway to Circumvent the Blood-Brain Barrier for Drug Delivery.
Ghazal Naseri Kouzehgarani, Pankaj Kumar, Susan E Bolin, Edward B Reilly, Didier R Lefebvre

Pharmaceutics· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 and Biodistribution Study of ABT-806i, an In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
Hui K Gan, Matthew Burge, Benjamin Solomon, Sze Ting Lee, Kyle D Holen, Edward B Reilly

J Nucl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
Mark G Anderson, Qian Zhang, Luis E Rodriguez, Claudie M Hecquet, Cherrie K Donawho, Edward B Reilly

BMC Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Kedar S Vaidya, Michael J Mitten, Adelyn L Zelaya-Lazo, Anatol Oleksijew, Cory Alvey, Edward B Reilly

J Neurooncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Mark G Anderson, Hugh D Falls, Michael J Mitten, Anatol Oleksijew, Kedar S Vaidya, Edward B Reilly

Mol Cancer Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.
Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K Gan, Edward B Reilly

Pharmaceuticals (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
John H Strickler, Colin D Weekes, John Nemunaitis, Ramesh K Ramanathan, Rebecca S Heist, Edward B Reilly

J Clin Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.
Kedar S Vaidya, Anatol Oleksijew, Lora A Tucker, William N Pappano, Mark G Anderson, Edward B Reilly

Pharmacology· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Glenwood D Goss, Everett E Vokes, Michael S Gordon, Leena Gandhi, Kyriakos P Papadopoulos, Edward B Reilly

Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Andrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, Hugh D Falls, Michael J Mitten, Edward B Reilly

Mol Cancer Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both -Amplified and c-Met-Overexpressing Tumors, Irrespective of Pathway Dependence.
Jieyi Wang, Mark G Anderson, Anatol Oleksijew, Kedar S Vaidya, Erwin R Boghaert, Edward B Reilly

Clin Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
Andrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, Michael J Mitten, Suzanne Norvell, Edward B Reilly

Mol Cancer Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
Jieyi Wang, Liliane Goetsch, Lora Tucker, Qian Zhang, Alexandra Gonzalez, Edward B Reilly

BMC Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of ABT-806 in subjects with advanced solid tumors.
James M Cleary, David A Reardon, Nilofer Azad, Leena Gandhi, Geoffrey I Shapiro, Edward B Reilly

Invest New Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Edward B Reilly, Andrew C Phillips, Fritz G Buchanan, Gillian Kingsbury, Yumin Zhang

Mol Cancer Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potency of erythropoietin-mimic antibodies correlates inversely with affinity.
Susan E Lacy, Peter J DeVries, Nancy Xie, Emma Fung, Richard R Lesniewski, Edward B Reilly

J Immunol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A potent erythropoietin-mimicking human antibody interacts through a novel binding site.
Zhihong Liu, Vincent S Stoll, Peter J Devries, Clarissa G Jakob, Nancy Xie, Edward B Reilly

Blood· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis